门冬胰岛素30治疗2型糖尿病疗效观察

    Clinical study on insulin analogue aspart 30 in the treatment of type 2 diabetes mellitus

    • 摘要: 目的:观察胰岛素类似物门冬胰岛素30治疗血糖控制较差的2型糖尿病患者的临床疗效、安全性及耐受性。方法:将40例2型糖尿病患者随机分为两组,B组于早、晚餐前30 min注射预混人胰岛素30R,A组于早、晚餐时注射门冬胰岛素30,药物剂量根据血糖高低调整,比较治疗后两组空腹血糖、餐后血糖、血糖达标时间、胰岛素用量、发生低血糖时血糖值。结果:门冬胰岛素30和预混人胰岛素30R两组均可有效降低血糖(P<0.01),降糖效果差异无统计学意义(P>0.05),门冬胰岛素30组发生低血糖时血糖值高于预混人胰岛素30R组(P<0.05),尤其是夜间严重低血糖水平的发生。结论:在2型糖尿病患者中应用门冬胰岛素30降糖效果显著,安全性高,患者耐受性和依从性好。

       

      Abstract: Objective:To observe the clinical therapeutic effects,safety and resistance of insulin analogue aspart 30 in treatment for type 2 diabetes mellitus.Methods:Forty patients with type 2 diabetes mellitus.were randomly divided into A group and B group,aspart 30 was used in A group patients while novolin 30R was used in B group patients,A group and B group patients were treated twice daily in morning and evening respectively.And the drug doses were adjusted momentarily according to the concentration of blood glucose in these patients.These parameters including the concentration of fasting plasma glucose (FPG),concentration of 2 hours postprandial glucose (2hPG),therapeutic time,insulin dose and the level of hypoglycemia were compared between these two groups.Results:Aspart 30 and novolin 30R could decrease the concentration of blood glucose efficiently (P<0.01),and there were no significant differences in these two groups (P>0.05).The level of hypoglycemia in aspart 30 group was higher than in novolin 30R group (P<0.05),especially the level of severe hypoglycemia at night.Conclusions:Aspart 30 is an effective and high safety drug in treatment for type 2 diabetes mellitus.The resistance and compliance of aspart 30 is better than novolin 30R.

       

    /

    返回文章
    返回